A research note on the six-plus pivotal readouts that will validate or break the 5-HT2A mechanism class over the next twelve months.
Compass Pathways' COMP360 is the only psychedelic to have produced Phase 3 registrational data, and the FDA granted a rolling NDA review in April 2026. The sector's investability now hinges on a single 12‑month window: six or more pivotal readouts across three sponsors in 2026 will either validate or break the 5‑HT2A mechanism class.
Three structural tensions define the risk–reward. First, functional unblinding — the FDA enforced this standard in the August 2024 Lykos CRL, and every surviving program must demonstrate its trial design can withstand the same scrutiny. Second, the clinic‑heavy delivery model requiring dual therapists and 4–8 hour sessions creates a commercial scaling constraint that approval alone does not solve. Third, capital runways are critically compressed: Compass holds roughly 3.8 quarters of cash against a Q4 2026 NDA target, and Cybin's $112M annual burn against a ~$280M market cap implies dilutive financing before its Phase 3 reads out.
The binary risk is narrow and explicit. If the COMP006 26‑week durability data (Q3 2026) shows efficacy waning to non‑significance, the rolling NDA stalls and the entire class faces a 12–18 month timeline extension that most sponsors cannot fund.
The psychedelic clinical pipeline is concentrated in severe neuropsychiatric disorders. Major Depressive Disorder (MDD) is the dominant indication — 6 of 16 active psychedelic trials target MDD directly. Generalized Anxiety Disorder (GAD) has emerged as the second major node, driven by Definium's DT120 Phase 3 program and Cybin's CYB004 Phase 2. Treatment-Resistant Depression (TRD) is the registrational focus for Compass Pathways' COMP360, though registry indexing often subsumes TRD under broader MDD labels.
PTSD is now a cautionary zone. Lykos Therapeutics' MDMA-assisted therapy was the most advanced PTSD program in the class, and its August 2024 FDA rejection (detailed in Section 2) has effectively frozen PTSD development for classical psychedelics. Sponsors are pivoting MDMA derivatives away from PTSD into Autism Spectrum Disorder (ASD) — Definium dosed its first patient in a Phase 2a DT402 (R-MDMA) ASD trial by January 2026.
Smaller exploratory programs target addiction, cancer-related adjustment disorder (Psyence Biomedical's PEX010), somatic indications including IBS and fibromyalgia (TRYP Therapeutics' TRP-8803), binge eating disorder, and rare neurodevelopmental conditions such as Fragile X Syndrome (Nova Mentis, though this program is now suspended). These remain early-stage and speculative.
All classical psychedelics share a primary pharmacological target: agonism at the serotonin 5‑HT2A receptor. This receptor activation drives both the acute subjective psychedelic experience and — critically — downstream neuroplasticity. Two landmark mechanistic findings define the current scientific understanding.
Vargas et al. (2023, Science, 436 citations) demonstrated that psychedelics promote neuroplasticity through activation of intracellular 5‑HT2A receptors, not cell-surface receptors. The hallucinogenic experience is mediated by cell-surface activation; the neuroplastic — potentially therapeutic — effects occur via the intracellular pathway. This dissociation is the foundational scientific rationale for non-hallucinogenic psychoplastogens.
Moliner et al. (2023, Nature Neuroscience, 414 citations) showed that psychedelics directly bind the TrkB receptor (BDNF receptor) with approximately 1,000-fold higher affinity than conventional antidepressants. This suggests a 5‑HT2A-independent neuroplasticity pathway that may contribute to therapeutic effects.
Esketamine (Spravato, NDA 211243, Janssen) is the only FDA-approved asset in the broader rapid-acting antidepressant class, approved in 2019 for TRD. It operates via NMDA receptor antagonism rather than 5‑HT2A agonism. Its REMS framework — mandatory in-clinic administration, 2-hour post-dose monitoring, restricted certified dispensing centers — serves as the regulatory and commercial precedent for all psychedelic approvals.
Mediates the acute subjective hallucinogenic experience — the source of the blinding problem.
Drives neuroplasticity — the putative therapeutic pathway. Foundation for non‑hallucinogenic psychoplastogens.
| Class | Lead assets | Session duration | Clinical maturity |
|---|---|---|---|
| Psilocybin / psilocin | COMP360, CYB003 | 4–6 hr | Phase 3 · most advanced |
| LSD analogs | DT120 (ODT) | ~8–12 hr | Phase 3 (GAD, MDD) |
| DMT & analogs | CYB004, SPL026, GH001 | ~20 min IV | Phase 1–2 · commercial edge |
| MDMA & derivatives | DT402 (R‑MDMA), MM402 | ~4 hr | Phase 2a · pivot to ASD |
| Esketamine (precedent) | Spravato · NDA 211243 | ~2 hr | Approved 2019 (TRD) |
Two emerging strategies aim to resolve the clinical and commercial constraints of classical psychedelics.
IV DMT compresses the psychedelic experience to approximately 20 minutes versus 4–6 hours for psilocybin. SPL026 (DMT fumarate) has published Phase 2a efficacy data (detailed in Section 4). This approach retains the hallucinogenic experience but dramatically reduces clinic time, therapist hours, and infrastructure burden. Ramaekers et al. (2025, Am J Psychiatry) explicitly articulated the clinical and operational advantages of this format.
Enabled by the Vargas et al. intracellular 5‑HT2A finding, these compounds aim to promote neuroplasticity without subjective psychedelic effects. If successful, they would eliminate the blinding problem entirely and enable conventional oral dosing. Sharp & Ippolito (2025, Br J Pharmacology) reviewed the preclinical landscape. The critical unresolved question is whether the subjective psychedelic experience is necessary for therapeutic efficacy — Hashimoto (2024, Eur Arch Psychiatry Clin Neurosci) posed this question directly, and the evidence remains genuinely ambiguous.
The Psychopharmacologic Drugs Advisory Committee voted 9–2 against approval. Primary deficiencies: functional unblinding, psychotherapy standardization, and safety characterization. MDMA remains Schedule I. This CRL reset the regulatory bar for the entire psychedelic class.
Classical psychedelics produce subjective effects so distinctive that traditional placebo controls cannot maintain blinding. This was the primary driver of the Lykos CRL. Hovmand et al. (2023, J Psychopharmacology) reviewed bias in psychedelic RCTs and concluded successful blinding remains a significant challenge, recommending parallel-group designs with active placebos. Loewinger et al. (2025, medRxiv) formalized a statistical framework for causal inference under functional unmasking — precisely because the challenge is so pervasive.
The Usona psilocybin trial (detailed in Section 4) illustrates both the design response and its limitations: niacin 100 mg was used as an active comparator, but 46% of psilocybin subjects reported "illusion" as an adverse event versus 5.6% for niacin. The perceptual effects remain qualitatively unmistakable. The FDA's June 2023 draft guidance on psychedelic clinical trials further requires sponsors to standardize and isolate the psychotherapy component — a demand that compounds the blinding challenge, since the therapy itself varies across sites and facilitators.
Müller et al. (2025, Med) attempted a different approach: low-dose LSD as an active placebo against high-dose LSD, acknowledging that inactive placebos cannot maintain the blind with hallucinogens. This is creative but imperfect — the low dose still produces some subjective effects, and if it has therapeutic activity, the design underestimates the high-dose treatment effect.
Esketamine (Spravato), introduced in Section 1 as the REMS precedent, established the operational template: mandatory in-clinic administration, strict 2-hour post-dose monitoring, and dispensing restricted to certified centers (NDA 211243, approved 2019). Psychedelics will face identical or more stringent REMS obligations. The critical difference is session duration: psilocybin requires 6–8 hours of supervised dosing versus 2 hours for esketamine, implying materially greater operational and cost burden per treatment.
Real-world esketamine data underscores the commercial friction ahead. Harding et al. (2024) found that patients generally required more time than the label recommendation to complete induction, with most undergoing 12 or more sessions — driving up acute healthcare resource use and costs. Clemens et al. (2024) documented significant disparities in esketamine initiation based on income and education, reflecting access and coverage gaps across commercial and Medicaid/Medicare populations. If esketamine's 2-hour REMS model already creates access barriers, psilocybin's 6–8 hour sessions will magnify them substantially.
Barnett (2023) explicitly highlights that psychedelic therapy's commercial viability depends on developing de novo CPT billing codes, because existing reimbursement structures cannot accommodate multi-hour supervised sessions. This billing infrastructure does not yet exist.
Visualised: in-clinic burden per dose under each program's design.
All classical psychedelics remain Schedule I controlled substances. Without FDA approval, rescheduling cannot occur — creating a regulatory catch-22. Every Phase 3 clinical site requires burdensome DEA licensing, which slows trial execution and increases costs. The Lykos CRL compounds this: MDMA remains Schedule I, and the newly mandated Phase 3 trial must navigate the same licensing gauntlet. This constraint applies equally to psilocybin, LSD, and DMT programs.
Despite the Lykos setback, the FDA has granted Breakthrough Therapy Designations to three psychedelic programs: COMP360 for TRD (Compass Pathways), CYB003 for MDD (Cybin), and psilocybin for MDD (Usona Institute). Compass also holds UK ILAP (Innovative Licensing and Access Pathway) status. Nova Mentis secured FDA and EMA Orphan Drug Designations for psilocybin in Fragile X Syndrome. Most significantly, the FDA granted Compass a rolling NDA review in April 2026 — a signal that the agency is willing to engage with psilocybin submissions despite the Lykos precedent, provided the trial design addresses blinding concerns.
The psychedelic development sector is structurally top-heavy. A small cohort of publicly traded companies — Compass Pathways, Definium Therapeutics, Cybin, and Atai Life Sciences — controls the majority of late-stage clinical programs. Behind them sits a long tail of private and micro-cap sponsors, mostly in Phase 1/2, with limited capital and high operational risk. Geographic concentration mirrors this structure: North America (US and Canada) dominates trial execution, with Europe (UK, Germany, Netherlands, Denmark, Spain) providing key secondary sites, and Australia emerging as a uniquely important regulatory jurisdiction.
MindMed officially rebranded to Definium Therapeutics (Nasdaq: DFTX) in January 2026. This resolves identity confusion across trial registries, where MM120 and DT120 refer to the same lysergide D-tartrate compound. All references in this report use the Definium name.
The formulation landscape is shifting from crude extracts to optimized, scalable formats. Definium's DT120 ODT (orally disintegrating tablet) and Compass's standardized COMP360 capsule reflect the commercial imperative for reproducible, GMP-grade dosing.
Definium's pipeline extends beyond DT120. DT402 (R-MDMA) dosed its first patient in a Phase 2a ASD trial by January 2026, confirmed in the rebrand press release. A second MDMA derivative, MM402, was planned for Phase 2a initiation in Q4 2025 per MindMed's Q3 2025 financial results. MM402 targets an undisclosed indication and represents Definium's second entactogen-class asset, broadening the MDMA-derivative portfolio beyond DT402's ASD focus.
Cybin's CYB003 MDD program is broader than a single trial. Three Phase 3 studies are registered: APPROACH (NCT06564818, n=220, topline Q4 2026), EMBRACE (NCT06793397, completion March 2027), and a third extension study (NCT06605105, completion March 2028). Total planned enrollment across the CYB003 Phase 3 program exceeds 600 participants.
| Company | Ticker | Lead asset(s) | Indication | Stage | Key status | HQ |
|---|---|---|---|---|---|---|
| Compass Pathways | CMPS | COMP360 (psilocybin) | TRD, MDD | Ph3 / Rolling NDA | FDA BTD · UK ILAP · Rolling NDA Apr '26 | London |
| Definium Therapeutics | DFTX | DT120 (LSD ODT), DT402, MM402 | GAD, MDD, ASD | Ph3 · Ph2a · Ph2a (planned) | MindMed rebrand Jan '26 | New York |
| Cybin | CYBN | CYB003 (deut. psilocin), CYB004 (DMT) | MDD, GAD | Ph3 (×3 trials), Ph2 | FDA BTD (CYB003, MDD) | Toronto |
| Atai Life Sciences | ATAI | Portfolio (incl. Beckley BPL‑003) | Multiple | Ph1–3 | — | Berlin |
| GH Research | GHRS | GH001 (5‑MeO‑DMT) | MDD | Phase 1 | NCT06511947 · UK · n=52 | Dublin |
| Algernon | AGN | DMT (IV) | Stroke, Depression | Phase 1 | — | Vancouver |
| TRYP Therapeutics | TRYP | TRP‑8803 (psilocybin) | IBS, Fibromyalgia, BED | Phase 2 | 393‑day delay | Toronto |
| Psyence Biomedical | PSYB | PEX010 (nature-derived psilocybin) | Adjustment disorder | Phase 2b | AU site initiated Sept '24 | Toronto |
| Reunion Neuroscience | REUN | RE‑104 | GAD | Phase 2 (not yet recruiting) | — | — |
| Company | Lead asset | Indication | Stage | Notable status | Geography |
|---|---|---|---|---|---|
| Lykos Therapeutics | MDMA (midomafetamine) | PTSD | Post‑CRL · new Ph3 required | FDA CRL Aug '24 · Schedule I | US |
| Usona Institute | Psilocybin | MDD | Phase 2 complete | FDA BTD (MDD) | US |
| Beckley Psytech | BPL‑003 | TRD, MDD | Phase 2 (n=64) | Atai portfolio · 1,127 delay days | UK |
| Small Pharma / Awakn / Helus | SPL026 (IV DMT) | MDD | Phase 2a published | MHRA Innovation Passport | UK / CA |
| Nova Mentis | Psilocybin | Fragile X Syndrome | Phase 2 · SUSPENDED | FDA/EMA Orphan · 715‑day dormancy | Canada |
| Apex Labs | Psilocybin | PTSD / Depression | Phase 2b | Health Canada NOL | Canada |
| Empower Research | Psilocybin | PTSD (first responders) | Phase 2 (n=32) | Canadian program | Canada |
| Queen's University | Psilocybin | GAD | Phase 2 | Health Canada NOL | Canada |
| Syndeio · Autobahn · Eleusis · Neurala | Undisclosed | Undisclosed | Phase 1–2 | Various registry | US |
The United States leads with 9 trial-country counts across the broad psychedelic registry, followed by Canada (2), the UK, Netherlands, and Australia. Psilocybin trials show a broader European footprint: Compass's Phase 3 COMP006 deployed sites across Czechia, Spain, Germany, Poland, Denmark, France, Sweden, Ireland, and the Netherlands. Health Canada is actively issuing No Objection Letters for Phase 2 psilocybin programs, including Apex Labs (PTSD/Depression), Queen's University (GAD), and Empower Research (PTSD in first responders).
In July 2023, Australia's Therapeutic Goods Administration (TGA) reclassified psilocybin and MDMA under the Authorised Prescriber scheme, allowing authorized psychiatrists to prescribe psilocybin for TRD and MDMA for PTSD outside clinical trials. Australia is the first and only country to permit legal prescribing of these substances in a clinical setting. The implications are two-fold: it provides an early real-world signal on clinical adoption, patient selection, and adverse event profiles that will inform FDA and EMA regulatory posture; and it creates a potential early commercial proof-of-concept for psilocybin-assisted therapy, albeit in a small market. Psyence Biomedical initiated its Phase 2b Australian site in September 2024, leveraging this framework.
Oregon's Measure 109 (passed 2020) and Colorado's Natural Medicine Health Act have established parallel state-level access pathways for psilocybin outside the FDA framework. Peer-reviewed analyses indicate that significant challenges have impeded implementation (Bellman, 2024). These include the absence of insurance reimbursement, complex state licensing, and difficulties establishing standardized dosing outside pharmaceutical supply chains. Siegel et al. (2022, JAMA Psychiatry) described the legislative reform as proceeding in a rapid, patchwork fashion.
The net effect is market segmentation rather than direct commercial cannibalization. FDA-approved psilocybin products will enter a traditional healthcare pathway with psychiatric prescribing, standardized REMS, and third-party payer reimbursement. State-level models, constrained by federal illegality and high self-pay costs, will serve a distinct demographic. The addressable commercial market for FDA-approved clinical psilocybin remains largely insulated from state-level wellness models.
Beyond the lead programs, registry behavioral data reveals a pattern of operational distress in the long-tail cohort that is material for assessing pipeline execution risk.
Enrollment expanded 5.3× (12 → 64) — the most volatile operational profile in the pipeline. Suggests fundamental protocol redesign or power shortfall. As an Atai portfolio asset, this signal has indirect readthrough to ATAI valuation.
Despite holding both FDA and EMA Orphan Drug Designations, the program appears functionally dead. Clearest example in the cohort of regulatory designations failing to translate into operational execution.
Attempting to expand psilocybin into somatic indications (IBS, fibromyalgia) where the mechanism-of-action rationale is weaker than in depression. Operational delay compounds the scientific risk.
Cybin's second-priority asset behind CYB003. If Phase 2 data (Q1 2026) disappoints, Cybin's pipeline diversification thesis narrows to CYB003 alone.
Beckley Psytech BPL‑003 (1,127 days), Nova Mentis Fragile X (715 days, suspended), Usona MDD (512 days), and TRYP IBS (393 days). The lead programs (Compass, Definium, Cybin CYB003) have not exhibited comparable distress, suggesting a sharp execution divide between well‑capitalized leaders and the micro‑cap tail.
Contrarian interpretation. Not all delay signals are equivalent. Usona's expansion preceded a successful readout; Beckley's 12→64 change could reflect an amendment that improved statistical power. The distinguishing feature appears to be whether the change accompanied a fundamental design shift (negative) versus a sample‑size increase within the same design (ambiguous).
The efficacy signal for psychedelics in depression is genuine and statistically robust. The methodological constraints — functional unblinding, psychotherapy variability, active comparator attrition — create interpretive uncertainty that the FDA is now formally scrutinizing. The evidence base is strongest for psilocybin, emerging for IV DMT, and entirely preclinical for non-hallucinogenic psychoplastogens.
This is the most detailed published psilocybin efficacy dataset. MADRS change from baseline: −19.1 for psilocybin versus −6.8 for niacin comparator. LS mean difference: −12.3 (95% CI: −17.5 to −7.2, p<0.001). The effect size is large and clinically meaningful. However, the blinding exposure is stark: 46% of the psilocybin arm reported "illusion" as an adverse event versus 5.6% for niacin. Niacin attrition was 20.8% (11/53) versus 2% (1/51) for psilocybin — a differential that could reflect demoralization from perceiving assignment to the control arm. Enrollment expanded 233.7% (from an initial target to 347 participants) with 512 cumulative delay days, signaling either expanded ambition after encouraging interim data or operational complexity in this facilitator-supervised design.
Both pivotal TRD trials met their primary endpoints. COMP005 (NCT05624268, n=255) demonstrated a −3.6 MADRS point reduction versus placebo (p<0.001). COMP006 (NCT05711940, n=581) demonstrated a −3.8 MADRS point reduction versus the 1mg control arm at Week 6 (p<0.001). These are the only Phase 3 registrational results for any classical psychedelic. The magnitude difference versus the Usona Phase 2 (−12.3 points) is analytically important: Phase 3 designs with stricter controls and larger samples typically produce smaller effect sizes than Phase 2 open-label-adjacent contexts. The 26-week durability data from COMP006, expected Q3 2026, is the critical remaining data point for the rolling NDA.
Compass's Phase 3 MADRS reductions of −3.6 and −3.8 points are statistically significant but modest in absolute terms. For reference, esketamine's pivotal trials showed MADRS reductions of ~4 points versus placebo. The 26-week durability readout (Q3 2026) will determine whether psilocybin's effect is durable enough to justify the operational burden of in-clinic administration — a 6-month observational follow-up against escitalopram already suggests parity at six months; COMP006's 26-week data would substantially strengthen the NDA if it confirms that signal in a controlled Phase 3 setting.
Direct comparison is confounded by population, sample size, and design heterogeneity. Phase 3 designs with stricter controls typically produce smaller effect sizes than Phase 2 contexts.
Definium's DT120 (formerly MM120, lysergide D-tartrate ODT) generated positive Phase 2 data in GAD that supported advancement to Phase 3. The three Phase 3 readouts — the Definium DT120 catalyst schedule described in Section 6 — are pending. No Phase 3 LSD analog data have been published.
MADRS difference: −7.35 versus placebo at 2 weeks (95% CI: −13.62 to −1.08, p=0.023). Published in Nature Medicine, February 2026. The psychedelic experience was compressed to approximately 20 minutes versus 4–6 hours for psilocybin. This is the most commercially significant design feature in the psychedelic pipeline: fewer therapist hours, shorter clinic occupancy, and potential compatibility with outpatient psychiatric settings. The effect size is smaller than the Usona psilocybin result (−12.3 points), though direct comparison is confounded by different populations, sample sizes, and trial designs. SPL028, a deuterated DMT analog, is in development to optimize the pharmacokinetic profile while retaining the short-acting format.
Esketamine FAERS data provides the class-level proxy for perceptual and cardiovascular adverse event burden: DISSOCIATION (3,351 reports), HYPERTENSION (688 reports), BLOOD PRESSURE INCREASED (518 reports). The Usona trial's cardiovascular exclusion criteria — banning participants with uncontrolled hypertension, coronary artery disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, MI, or tachycardia — reveal the sponsor's awareness of acute CV risk.
Rouaud et al. (2024, J Psychopharmacology) specifically examined 5‑HT2B valvulopathy risk from chronic psychedelic microdosing, comparing exposure to known cardiotoxins. This risk is distinct from the single therapeutic dose profile: single-session psilocybin carries minimal chronic 5‑HT2B exposure, but repeated dosing protocols or compounds with significant 5‑HT2B affinity (LSD has measurable 5‑HT2B agonism) face a different risk calculus.
The 5‑HT2A/TrkB/BDNF mechanisms described in Section 1 provide the scientific rationale for non-hallucinogenic psychoplastogens. No human clinical efficacy data have been published for any such compound. The mechanistic case exists, but clinical maturity lags the IV DMT approach by several years. Whether the subjective psychedelic experience is necessary for therapeutic efficacy remains genuinely unresolved (Hashimoto, 2024).
The capital intensity of psychedelic Phase 3 trials is structurally higher than conventional CNS programs. Multi‑site execution with trained facilitators, extended in‑clinic dosing sessions (4–8 hours per patient), and DEA Schedule I licensing requirements create burn dynamics that compress runways. The financial stratification across the public cohort is stark.
| Company | Ticker | Market cap | Cash / net cash | Quarterly burn | Runway (Q) | Risk |
|---|---|---|---|---|---|---|
| Compass Pathways | CMPS | ~$1.27B | ~$150M | ~$39.3M | ~3.8 | HIGH — likely raise before NDA |
| Definium Therapeutics | DFTX | ~$2.26B | ~$309M† | n/a | n/a | MODERATE — 3× concurrent Ph3 |
| Atai Life Sciences | ATAI | — | ~$256M | ~$25.7M | ~10.0 | LOW — covered through 2028 |
| Cybin | CYBN | ~$280M | — | ~$28.0M | unclear | HIGH — burn/cap ratio severe |
† Implied net cash derived from $2.26B market cap − $1.95B enterprise value; not balance‑sheet confirmed.
Compass's tight 3.8-quarter runway against a Q4 2026 NDA submission target is the critical financial tension. The rolling NDA grant buys regulatory credibility but not cash. A dilutive raise or partnership announcement before year-end 2026 is the base-case expectation.
Atai's portfolio approach — multiple early-stage assets including Beckley Psytech's BPL-003 — provides optionality and a 10-quarter runway that insulates it from near-term financing pressure. It is the only public sponsor not on the dilution countdown.
Cybin's −$112M annual burn relative to ~$280M market cap is the starkest risk in the cohort; funding the APPROACH Phase 3 through Q4 2026 topline will likely require highly dilutive financing unless non-dilutive partnership capital is secured.
Definium's financial position is the most important partial gap in this analysis. An implied net cash position of ~$309M is derived from a $2.26B market cap and $1.95B enterprise value. This is substantial, but the company is simultaneously funding three Phase 3 trials with combined enrollment exceeding 600 patients. Without the quarterly burn rate from SEC filings, precise runway cannot be calculated. The $309M cash position against three concurrent pivotal programs suggests Definium is better capitalized than Compass or Cybin, though not immune to financing pressure if trials extend beyond Q3 2026.
Consolidation or licensing partnerships are the likely resolution path for capital-constrained sponsors. Lykos Therapeutics — now requiring a new Phase 3 trial with no approved product and MDMA still Schedule I — represents the worst-case capital outcome in the sector.
The 2026 readout cluster is an unusually concentrated period of pivotal data in psychedelic drug development. Six or more Phase 2/3 readouts across three sponsors target overlapping 5‑HT2A indications within a single calendar year.
The 5‑HT2A mechanism is shared across COMP360, DT120, and CYB003. A surprising failure in any one program — especially on safety grounds — would pressure peer valuations regardless of compound‑specific differentiation. The readthrough is asymmetric: a safety signal would propagate across the class more aggressively than an efficacy miss, which could be attributed to compound‑specific pharmacology or trial design. Conversely, Compass's positive Phase 3 results already create bullish readthrough for Cybin, Atai/Beckley, and GH Research in the TRD/MDD space.
| Triggering event | Compass CMPS | Cybin CYBN | Definium DFTX | Atai ATAI | GH Research GHRS |
|---|---|---|---|---|---|
| Compass 26-wk durability miss Q3 2026 |
Severe ↓ | Material ↓ | Moderate ↓ | Moderate ↓ | Limited |
| Class-wide safety signal cardiac · psychiatric AE |
Severe ↓ | Severe ↓ | Severe ↓ | Severe ↓ | Material ↓ |
| Cybin CYB003 Phase 3 readout 2H 2026 / 1H 2027 |
Positive ↑ | Severe ↑↓ | Moderate ↑ | Moderate ↑ | Limited |
| Definium DT120 GAD readout 2H 2027 |
Limited | Limited | Severe ↑↓ | Limited | Limited |
| FDA REMS framework finalized if burden > esketamine |
Material ↓ | Material ↓ | Material ↓ | Material ↓ | Material ↓ |
| Sponsor | Program · Indication | Status / Catalyst | P(Readouton time) | P(Endpointmet) | P(USapproval) | Key signal · risk |
|---|---|---|---|---|---|---|
| Public sponsors · late stage | ||||||
|
Compass Pathways
CMPS
|
COMP005
|
Readout · success
NDA filing Q4 '26
|
55–65% | MADRS Δ −3.6 met. NDA gated by COMP006 26-wk. | ||
|
Compass Pathways
CMPS
|
COMP006
|
Part A · success
26-wk · early Q3 '26
|
65–75% | 65–75% | 55–65% | 337-day op delay; durability anchored to esketamine class. |
|
Definium
DFTX
|
DT120 Voyage
|
Recruiting · pulled-in
Topline Q2 '26
|
65–75% | 55–65% | 35–50% | First Ph3 LSD readout ever; 226-day pull-in is bullish. |
|
Definium
DFTX
|
DT120 Emerge
|
Active, not recruiting
Topline H2 '26
|
70–80% | 50–60% | 30–45% | Cleanest ops profile in cohort; ops risk 0/100. |
|
Definium
DFTX
|
DT120 Panorama
|
Recruiting · 6-country
Topline H2 '26
|
55–65% | 50–60% | 30–45% | Replication; outcome highly correlated with Voyage. |
|
Cybin
CYBN
|
CYB003 APPROACH
|
Recruiting · 153d delay
Topline Q4 '26
|
55–65% | 70–80% | 60–70% | Strong drug, weak ops. 0/8 Cybin commitments resolved. |
|
Cybin
CYBN
|
CYB003 EMBRACE
|
Active
Completion Mar '27
|
45–55% | 55–65% | 30–45% | Confirmatory; tightly correlated with APPROACH. |
|
Cybin
CYBN
|
CYB004
|
Active · 389d delay
Data emergence '26
|
20–30% | 45–55% | — | 4 missed readout commitments; risk score 70/100. |
| Sponsor | Program · Indication | Status / Catalyst | P(Readouton time) | P(Endpointmet) | P(USapproval) | Key signal · risk |
|---|---|---|---|---|---|---|
| Public sponsors · earlier stage | ||||||
|
GH Research
GHRS
|
GH001
|
PK study · UK
PK completion
|
70–80% | — | 35–45% | Aerosol delivery differentiator; awaiting Ph2 TRD data. |
|
Psyence Bio
PSYB
|
PEX010
|
Recruiting · 223d delay
Topline Q4 '26
|
45–55% | 45–60% | 10–20% | 3rd guidance iteration. Australia-only; credibility 0.0. |
|
Reunion Neuro.
REUN
|
RE-104
|
Recruiting
Readout '26–'27
|
55–65% | 45–55% | — | Moderate landscape risk; n not publicly reported. |
| Private / non-listed | ||||||
|
Lykos
|
Midomafetamine
|
New Ph3 required
Type A meeting
|
— | prior Ph3 | 25–35% | Regulatory failure not data failure. 5-year horizon. |
|
Small Pharma / Helus
|
SPL026
|
Readout · success
HLP004 GAD missed
|
15–25% | Nature Med Feb '26. n=34. UK MHRA only; no US IND. | ||
|
Usona Institute
|
NCT03866174
|
Completed Jun '22
Awaiting publication
|
60–70% | 55–65% | 30–40% | Enrollment +233.7%; non-profit needs commercial partner. |
|
Tryp Therapeutics
|
TRP-8803
|
Active · 393d delay
Possibly '26
|
45–55% | 65–75% | 15–20% | n=14. Endpoint is safety/tolerability, not efficacy. |
Mandatory in‑clinic administration under REMS; trained therapist per session; 4–8 hour session duration versus 2 hours for esketamine; dual‑therapist models; no self‑administration pathway. A single certified clinic running 2 dosing rooms, 8‑hour sessions, 5 days/week can serve roughly 10 patients per week — versus thousands of TRD patients per region. This is not a regulatory problem; it is a structural economics problem that approval does not solve. Barnett (2023): de novo CPT billing codes must be developed before payer reimbursement is possible.
IV DMT is the most credible near‑term response to the scaling problem. The SPL026 data demonstrated efficacy with a ~20‑minute session, potentially compatible with outpatient psychiatric settings and dramatically improving clinic throughput. If IV DMT efficacy proves durable, it could reshape the commercial model from a specialty‑center paradigm to something closer to Spravato's existing infrastructure.
| Path | Trigger | Affected assets | Portfolio implication |
|---|---|---|---|
| 1. Class-wide safety signal | Unexpected SAE in any '26 readout (serotonin syndrome, psychotic break, CV event) | COMP360 · DT120 · CYB003 · CYB004 · BPL‑003 · GH001 | 30–50% sector de-rating for single-asset sponsors |
| 2. Durability failure | COMP006 26‑wk data shows efficacy waning to non-significance | Psilocybin class; readthrough to DT120, CYB003 | NDA stalls; +12–18 months to timelines; runway crisis |
| 3. Payer rejection | Major payers decline full therapy bundle under REMS | All approved assets | $15–30K per course faces prior‑auth barriers; uptake constrained |
On available data, Definium (DFTX) enters 2026 with the densest catalyst calendar (3× Phase 3) and — per the market-derived estimate flagged in §5 — the strongest implied capital position in the public cohort. Compass carries the first registrational data package and the rolling NDA; Cybin carries independent MDD optionality against the tightest burn-to-cap ratio. These are three different risk profiles, not a ranking.
The analytically load-bearing question across all three is the same: does the 2026 data cluster reproduce COMP360's efficacy signal under trial designs the FDA regards as adequately blinded? Voyage (Q2) and COMP006 26-week (Q3) are the two readouts that most materially move that question. APPROACH (Q4) is corroborating rather than gating.
Position sizing, hedging structures, and relative-value expression are outside the scope of this note. The Definium net-cash figure is market-derived rather than filing-sourced (see §5); readers should treat it accordingly pending the next 10-Q.
A class‑wide safety signal from any 2026 readout would re-rate the entire sector simultaneously. This correlation is itself the most important risk-management input for sector-level exposure — not the merits of any individual program.
| Gap | Section | Impact on conclusions |
|---|---|---|
| Non-hallucinogenic psychoplastogen clinical evidence partial; no human efficacy data published | §1 Thematic Map | Limits assessment of the non-hallucinogenic pivot as a near-term commercial strategy |
| Specific REMS requirements for psilocybin/LSD not formally proposed by FDA | §2 Regulatory | Commercial burden could be materially higher than the esketamine proxy implies |
| Private company enumeration incomplete; registry under-captures stealth players | §3 Company Landscape | Competitive landscape may be more crowded at Phase 1/2 than represented |
| Long-term safety data for repeated doses absent; 5-HT2B valvulopathy signal cannot be extrapolated | §4 Clinical Evidence | Chronic or repeat-use indications carry unquantified safety tail risk |
| Ph3 registrational data exist only for COMP360; all others pending '26 readouts | §4 Clinical Evidence | Sector-wide validation depends on a single 12-month window |
| Definium (DFTX) quarterly burn not available from SEC filings; $309M is market-derived | §5 Financial Health | Runway risk for most active '26 sponsor cannot be precisely assessed |
| Partnership economics not captured for any named public company | §5 Financial Health | Runway estimates may understate capital available to some sponsors |
| Enrollment completion & interim schedules for Cybin EMBRACE and Definium GAD Ph3 unconfirmed | §6 Catalyst Calendar | Catalyst timing estimates carry ±1-quarter uncertainty |
| Payer reimbursement and access modeling under REMS not publicly disclosed | §7 Scenario Analysis | Commercial uptake in bull case is highly uncertain; TAM could be severely constrained |
| Australia TGA Authorised Prescriber real-world outcomes data not yet published | §3 Geographic Focus | Early commercial signal from AU's unique framework is not yet quantifiable |